Pathogen News and Research

RSS

Biomagnetics Diagnostics to accelerate development of assay test cartridge for malaria, HIV/AIDS, hepatitis and TB

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for malaria, HIV/AIDS, hepatitis, tuberculosis and detection, announced today the implementation of a program to accelerate the availability of the world's first Integrated Optical BioSensor (IOBS) platform. The Company is currently reviewing research and manufacturing partnerships to develop simple to replicate bench top versions of the IOBS platform on which single pathogen or multiple pathogen testing assay cartridges can be developed.

11 Feb 2010

Cerus enters into collaborative agreement with EFS for development of INTERCEPT Blood System

Cerus Corporation announced today that it has entered into a collaborative agreement with France's national transfusion service, the Etablissement Français du Sang (EFS), for the development of the company's INTERCEPT Blood System for red blood cells.

10 Feb 2010

Mutations that enable Pseudomonas to thrive in cystic fibrosis lung secretions may also guard them against antibiotics

People with cystic fibrosis, an inherited disease that clogs airways with thick mucous, frequently have lung infections that defy treatment. While the life expectancy for children with cystic fibrosis has increased over the past few decades, many lives are still shortened in young adulthood by the ravages of lung infections.

10 Feb 2010

Preliminary study results of ExThera Medical's Seraph extracorporeal affinity therapy published

ExThera Medical announced today that the results of a preliminary study (“Cytokines in blood from septic patients interact with surface immobilized heparin”) of its proprietary medical device, Seraph™ extracorporeal affinity therapy, have been published in the current issue of the Journal of the American Society for Artificial Organs (Jan.-Feb. 2010).

9 Feb 2010

Phase 1 trial of Cerus' INTERCEPT red blood system meets primary endpoint

Cerus Corporation announced today that its Phase 1 trial of red blood cells treated with the INTERCEPT Blood System met its primary endpoint, with preliminary analysis demonstrating that greater than 75 percent of treated cells continued to circulate 24 hours following transfusion. The INTERCEPT red blood cell system is a pathogen inactivation treatment the company is developing to protect against transmission of infectious diseases through red blood cell transfusions. An estimated 70 million units of red blood cells are transfused worldwide each year.

9 Feb 2010

Studies suggest potential therapeutic targets for food poisoning, TB and autoimmune diseases

Researchers at National Jewish Health have discovered how the virulent food-borne bacteria Listeria monocytogenes induces infected immune cells to sabotage their own defensive response.

2 Feb 2010

Study could help in developing therapeutic strategies for Chikungunya virus infection

A study published online on February 1 in the Journal of Experimental Medicine (www.jem.org) shows that antiviral proteins called type I interferons (IFNs) are needed to fend off infection with an exotic mosquito-borne virus called Chikungunya virus.

2 Feb 2010

Mechanical tenderization linked to E. coli outbreaks, safe food attorney calls for specific FSIS label

Safe food attorney Bill Marler has called for the USDA’s Food Safety and Inspection Service (FSIS) to label meats that have undergone mechanical tenderization. The controversial process has been linked to numerous outbreaks of the dangerous pathogen E. coli O157:H7, yet there is currently no disclosure required.

29 Jan 2010

Universal Detection Technology responds to the U.S. Government's failure to address bioterrorism

Universal Detection Technology (www.udetection.com), a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats and provider of counter-terrorism consulting and training services, responded today to a bipartisan congressional committee’s scathing report card failing the U.S. Government for adequately preparing the country for the threat of a bioterrorism attack.

29 Jan 2010

Experimental vaccine protects mice and monkeys against chikungunya virus

An experimental vaccine developed using non-infectious virus-like particles (VLP) has protected macaques and mice against chikungunya virus, a mosquito-borne pathogen that has infected millions of people in Africa and Asia and causes debilitating pain, researchers at the National Institutes of Health have found.

29 Jan 2010

Researchers use high resolution genome sequencing to track virulent strain of MRSA

An international team of researchers has used high resolution genome sequencing to track a particularly virulent strain of MRSA as it traveled between South America, Europe and Southeast Asia.

27 Jan 2010

Genome study could help prevent devastating epidemics in the future

A team of collaborating scientists at The Methodist Hospital Research Institute in Houston, the Broad Institute in Boston, Mount Sinai Hospital in Toronto, and the Ontario Agency for Health Protection and Promotion (OAHPP) have sequenced almost 100 full genomes from three successive epidemics of flesh-eating bacteria.

27 Jan 2010

HZI researchers explore novel therapies to keep the immune system young and functional for healthy aging

By comparing the immune responses of both, young and old mice, to bacterial infection they found that the number of macrophages, one of the major cell populations involved in the elimination of infecting bacteria, decreases rapidly in aged mice. This decline in the number of fighters and the associated weakness of the immune defense may be responsible for the age-associated increase in susceptibility to infections.

27 Jan 2010

Ecolab and AvidBiotics to develop new technology to reduce E. coli in red meat products

Ecolab Inc. has entered into an agreement with AvidBiotics Corp. under which they will jointly work to develop a new technology that could significantly reduce the presence of the pathogen E. coli O157:H7 in red meat products.

27 Jan 2010

Current research suggests flu may predispose to secondary bacterial infections

Current research suggests that the flu may predispose to secondary bacterial infections, which account for a significant proportion of mortality during flu pandemics. The related report by Lee et al, "A mouse model of lethal synergism between influenza virus and Haemophilus influenzae," appears in the February 2010 issue of The American Journal of Pathology.

22 Jan 2010

Babraham Institute research may lead to new means of making purified T cells

Research from the Babraham Institute, reported today in the Journal of Experimental Medicine, provides new insights into how our immune system produces T cells, a type of white blood cell that is an essential part of the body's immune surveillance system for fighting infection. The findings pave the way for a new means of making purified T cells, which gets over one of many hurdles faced in the use of T cells in regenerative medicine and transplantations, and in addition will open up new avenues of research and applications in drug and toxicity testing in industry.

18 Jan 2010

Scientists discover new mechanism that explains role of EBV in tumor growth

The Epstein-Barr virus (EBV), a virus of the herpes family, has two distinct life phases: After infecting a cell it first goes into a resting phase. Under certain circumstances the virus can become active - and then induces tumor growth or promotes its synthesis in the cell.

18 Jan 2010

Cerus' INTERCEPT platelets therapeutically effective even after seven days of storage

Cerus Corporation announced today that INTERCEPT-treated platelet components were found to be effective for patient support following extended six and seven day storage in a clinical study conducted at four sites in Europe. These data further confirm the safety and therapeutic efficacy of platelets treated with the INTERCEPT Blood System, a pathogen inactivation treatment designed to protect against transfusion-transmitted diseases.

18 Jan 2010

AvidBiotics and Ecolab to develop new technology that reduces food pathogens in meat products

AvidBiotics Corp. and Ecolab Inc. today announced an agreement under which they will work to develop a new technology to dramatically reduce the presence of the dangerous pathogen E. coli O157:H7 in red meat products.

12 Jan 2010

Clinical Foundations' edition provides comprehensive review of hospital-acquired infections

Clinical Foundations, a patient-focused education program dedicated to helping respiratory care professionals stay current on clinical trends, has recently published a new edition titled “Pathogens Associated with the Intensive Care Unit Environment –Considerations for the Respiratory Therapist.”

9 Jan 2010

Pathogen News and Research

Biomagnetics Diagnostics to accelerate development of assay test cartridge for malaria, HIV/AIDS, hepatitis and TB

Cerus enters into collaborative agreement with EFS for development of INTERCEPT Blood System

Mutations that enable Pseudomonas to thrive in cystic fibrosis lung secretions may also guard them against antibiotics

Preliminary study results of ExThera Medical's Seraph extracorporeal affinity therapy published

Phase 1 trial of Cerus' INTERCEPT red blood system meets primary endpoint

Studies suggest potential therapeutic targets for food poisoning, TB and autoimmune diseases

Study could help in developing therapeutic strategies for Chikungunya virus infection

Mechanical tenderization linked to E. coli outbreaks, safe food attorney calls for specific FSIS label

Universal Detection Technology responds to the U.S. Government's failure to address bioterrorism

Experimental vaccine protects mice and monkeys against chikungunya virus

Researchers use high resolution genome sequencing to track virulent strain of MRSA

Genome study could help prevent devastating epidemics in the future

HZI researchers explore novel therapies to keep the immune system young and functional for healthy aging

Ecolab and AvidBiotics to develop new technology to reduce E. coli in red meat products

Current research suggests flu may predispose to secondary bacterial infections

Babraham Institute research may lead to new means of making purified T cells

Scientists discover new mechanism that explains role of EBV in tumor growth

Cerus' INTERCEPT platelets therapeutically effective even after seven days of storage

AvidBiotics and Ecolab to develop new technology that reduces food pathogens in meat products

Clinical Foundations' edition provides comprehensive review of hospital-acquired infections

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News